SEC Comment Letter for SANGAMO THERAPEUTICS, INC (SGMO) (CIK 0001001233) (SGMOQ) — Nov 18, 2024
SANGAMO THERAPEUTICS, INC (SGMO) (CIK 0001001233)
Date: Nov. 18, 2024 · CIK: 0001001233 · Accession: 0000000000-24-012727
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283179
Letter
November 18, 2024 Alexander D. Macrae Chief Executive Officer Sangamo Therapeutics, Inc. 501 Canal Blvd. Richmond, CA 94804 Re:Sangamo Therapeutics, Inc. Registration Statement on Form S-3 Filed November 12, 2024 File No. 333-283179 Dear Alexander D. Macrae: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Courtney Tygesson, Esq.
Show Raw Text
November 18, 2024
Alexander D. Macrae
Chief Executive Officer
Sangamo Therapeutics, Inc.
501 Canal Blvd.
Richmond, CA 94804
Re:Sangamo Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 12, 2024
File No. 333-283179
Dear Alexander D. Macrae:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Courtney Tygesson, Esq.